PBF 1650

Drug Profile

PBF 1650

Alternative Names: PBF-1650

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Palobiofarma
  • Class Antipsoriatics; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Immune thrombocytopenic purpura; Psoriasis

Most Recent Events

  • 20 Oct 2017 Preclinical trials in Immune thrombocytopenic purpura in Spain (PO) before October 2017 (Palobiofarma pipeline, October 2017)
  • 20 Oct 2017 Preclinical trials in Psoriasis in Spain (PO) before October 2017 (Palobiofarma pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top